Eli Lilly & CO Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NYSE
Eli Lilly and Company has reported a beneficial ownership of 7.3% in Scribe Therapeutics, Inc. following its IPO, acquiring shares through a convertible note conversion and direct purchase.
NYSE
Eli Lilly and Company has reported a significant 11.9% beneficial ownership in Aktis Oncology, Inc. following its initial public offering.